A controlled in vitro hypersensitivity assessment in subjects previously treated whit the combination of GLPG3067 and GLPG2222, or the combination of GLPG3067, GLPG222 and GLPG2737 using Lymphocyte Transformation Test.

Conditions: Skin reaction (e.g. rash)
10014982

Registration Number: NL-OMON45940

Lead Sponsor: Galapagos N.V.

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: Not specified

Target Recruitment: 2

Inclusion Criteria

- trial subjects: subjects who participated in Part 4 or Part 5 of the GLPG3067 -CL -101 or the GLPG3067-CL-108 clinical trial and developed skin reactions suspected as drug hypersensitivity, OR
-control subjects: subjects who participated in Part 4 or Part 5 of the GLPG3067- CL- 101 or the GLPG3067-CL-108 clinical trial and did not develop any skin reaction or drug hypersensitivity signs.;- Able and willing to comply with the protocol requirements and to sign the ICF as approved by the Independent Ethics Committee (IEC), before any study-related procedures are performed.

Exclusion Criteria

- Any condition or circumstances that in the opinion of the investigator may make a subject unlikely or unable to complete the study or comply with study procedures and requirements.

Study & Design

Study Type: Observational invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>For this follow-up study, blood will be collected and this blood will be used<br /><br>for a so called lymphocyte transformation test (LTT). The LTT is a useful test<br /><br>for the diagnosis of drug hypersensitivity. The LTT will be done in order to<br /><br>better understand the cause of these hypersensitivity skin reactions.</p><br>

Secondary Outcome Measures